Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 298 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Contraceptive Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

NCT07525791
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0662-0419, Oral contraceptive, Acetaminophen
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Obesity, Oral Contraception, and Ovarian Suppression

NCT00827632
View directory record Official record
Conditions
Ovarian Suppression
Interventions
Low dose formulation, High dose formulation
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262740
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
South Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 2, 2026, 10:03 AM EDT
Active, not recruiting Phase 1 Interventional

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

NCT07523711
View directory record Official record
Conditions
Overweight, Obesity
Interventions
COC, Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 2, 2026, 10:03 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

NCT02735629
View directory record Official record
Conditions
Opiate Induced Respiratory Depression
Interventions
CX1739 - 300 mg, CX1739 - 600 mg, CX1739 - 900 mg, Placebo
Drug
Lead sponsor
RespireRx
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction

NCT04396730
View directory record Official record
Conditions
Contraception
Interventions
Cannabidiol Oil, Placebo, Combined oral contraceptive pill
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 2, 2026, 10:03 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo

NCT06162611
View directory record Official record
Conditions
Emergency Contraception
Interventions
Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg, Etonogestrel implant with oral placebo
Drug · Device
Lead sponsor
Lori Gawron
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 2, 2026, 10:03 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

NCT05303636
View directory record Official record
Conditions
Change in Bone Mineral Density, Bone Loss
Interventions
drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
1,536 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
27
States / cities
Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 2, 2026, 10:03 AM EDT
Withdrawn Phase 4 Interventional

Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients

NCT00826839
View directory record Official record
Conditions
Infertility
Interventions
Oral contraceptive pill and microdose lupron, E2 patch/antagonist
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Zibotentan, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 2, 2026, 10:03 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz

NCT01980342
View directory record Official record
Conditions
Drug Interaction
Interventions
Efavirenz
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

NCT01252186
View directory record Official record
Conditions
Hemostasis, Oral Contraceptive
Interventions
91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Sep 2, 2026, 10:03 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement for Premature Ovarian Insufficiency

NCT02922348
View directory record Official record
Conditions
Primary Ovarian Insufficiency
Interventions
Hormone Replacement Therapy, Combined Oral Contraceptives
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 2, 2026, 10:03 AM EDT
Terminated Not applicable Interventional

Family Planning Counseling for Women With Chronic Medical Conditions in an Inpatient Setting

NCT05859087
View directory record Official record
Conditions
Chronic Disease
Interventions
Counseling, Flyer
Behavioral
Lead sponsor
Sutter Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives in the Metabolic Syndrome

NCT00205504
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance, Obesity, Cardiovascular Diseases
Interventions
Ortho Tri Cyclen
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of Danicopan

NCT04709094
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Warfarin, Bupropion, Ethinyl Estradiol/Norethindrone
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)

NCT03608241
View directory record Official record
Conditions
Healthy Females
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonogestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 2, 2026, 10:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hormone Induced Effects on Ligament Laxity and Lower Extremity Motor Control

NCT04055129
View directory record Official record
Conditions
Hormone Influence on Ligament Laxity and Motor Control
Interventions
No interventions
Other
Lead sponsor
University of St. Augustine for Health Sciences
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Marcos, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 2, 2026, 10:03 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age

NCT03905941
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral combined hormonal contraceptives
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 2, 2026, 10:03 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Hyperemesis Gravidarum Risk Reduction With Metformin

NCT07129473
View directory record Official record
Conditions
Hyperemesis Gravidarum
Interventions
Metformin Extended Release Oral Tablet
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

NCT02641990
View directory record Official record
Conditions
Healthy Adult Premenopausal Female Volunteers
Interventions
ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 2, 2026, 10:03 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Estrogen and Microvascular Function

NCT06043310
View directory record Official record
Conditions
Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
Interventions
Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Effects of Opioid Administration

NCT03801629
View directory record Official record
Conditions
Drug Effect
Interventions
High Morphine Dose, Low Morphine Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 2, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

NCT00117273
View directory record Official record
Conditions
Healthy
Interventions
Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE)
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 2, 2026, 10:03 AM EDT